Diagnostics

SOBA Diagnostics

Highly sensitive, simple blood tests in development to aid in the early detection of amyloid diseases.

Simple. Different.

Diagnostics/biomarkers for amyloid diseases, in development to provide:

Early detection.  Tx efficacy tracking.  Clinical endpoints.

α-sheet target detection

Learn More

Blood-based assay

Learn More

Early, disease-specific detection

Learn More

High sensitivity and specificity

Learn More

α-sheet

The discovery of α-sheet led to a target for selective and early detection of toxic soluble oligomers. AltPep’s customized peptides serve as a capture agent for their detection. The presence of α-sheet toxic oligomers in blood, as detected with our SOBA assay, is highly correlated with Alzheimer’s, Parkinson’s and other amyloid diseases.

Blood-based assay

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer’s disease in clinical practice and to detect relevant disease-modifying effects of new drugs or lifestyle interventions. (Nature Aging, May 2023).

Early, disease-specific detection

While there are a number of CSF and blood-based biomarkers currently available across the clinical continuum of Alzheimer’s disease, AltPep’s blood-based SOBA-AD test is unique. Granted FDA Breakthrough Device designation, the SOBA-AD test is in development for early and disease-specific detection. 

AltPep’s SOBA assay is also in development for early detection of Parkinson’s disease and has potential application for many other amyloid diseases.

High Sensitivity and Specificity

The SOBA-AD test has demonstrated 99% sensitivity and 99% specificity, across multiple sites with multiple operators, as reported in two peer-reviewed papers. 

https://www.pnas.org/doi/epub/10.1073/pnas.2213157119

https://www.nature.com/articles/s41598-024-57107-w

Learn about our therapeutics, too.

Go to Therapeutics

The Risk of AIRA

Amyloid plaque are targeted and mobilized by anti-amyloid antibodies (such as lecanamab and donanamab). The antibody-bound plaque clear through the brain’s immune cells, called microglia, by binding Fc-gamma Receptors (FCgRs). (Alzheimers Dis Rep. 2023) This binding alters the microglia resulting in inflammation and cytokine storm and thereby creating a high risk of ARIA (https://ajronline.org/doi/epdf/10.2214/AJR.22.28461).

Linkedin-in

Valerie Daggett, PhD

Chief Executive Officer

Valerie, the CEO/Founder of AltPep and an Endowed Professor of Bioengineering at the University of Washington, has been a champion of groundbreaking research for over 30 years. Her inherent curiosity pushes her to uncover new ways of tackling problems in the field of amyloid diseases, where successes are few.  Her tenacity led to a revolutionary discovery of a protein structure that could dramatically change the diagnosis and treatment of Alzheimer’s disease and over 50 other amyloid diseases. At AltPep, Valerie leads a team of innovators who are developing this platform to make the early, pre-symptomatic diagnosis and treatment of amyloid diseases a reality. Valerie holds a BA from Reed College, PhD from the University of California, San Francisco, and was a Postdoctoral Fellow at Stanford University.